ArticlePhysiological reports2018
Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice.
Article in Physiological reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial.American journal of physiology. Regulatory, integrative and comparative physiology · 2021Trial
- Article
- Article
- Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency.Scientific reports · 2023Article
- Managing the Dual Nature of Iron to Preserve Health.International journal of molecular sciences · 2023Review
- Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.American journal of hematology · 2022Article
- Insights from the use of erythropoietin in experimental Chagas disease.International journal for parasitology. Drugs and drug resistance · 2022Article
- Iron Mining for Erythropoiesis.International journal of molecular sciences · 2022Review
- Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice.Blood · 2022Article
- Effect of Erythropoietin on the Expression of Murine Transferrin Receptor 2.International journal of molecular sciences · 2021Article
- Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.Journal of cellular physiology · 2021Review
- The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance.International journal of molecular sciences · 2021Review
- Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure.Haematologica · 2021Article
- Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone.PloS one · 2021Article
- Intravenous transfusion of iron sucrose reduces blood transfusions and improves postoperative anaemia after a second thoracotomy: a propensity-score matching study.The Journal of international medical research · 2020Article
- GDF11 contributes to hepatic hepcidin (HAMP) inhibition through SMURF1-mediated BMP-SMAD signalling suppression.British journal of haematology · 2020Article
- Myonectin deletion promotes adipose fat storage and reduces liver steatosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Effect of stimulated erythropoiesis on liver SMAD signaling pathway in iron-overloaded and iron-deficient mice.PloS one · 2019Article
- Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice.Physiological reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Erythropoietin (EPO) acts on erythroid progenitor cells to promote their survival and differentiation to mature erythrocytes. Along with this canonical role, EPO is also reported to modulate energy metabolism, resulting in improved glucose tolerance and insulin sensitivity. EPO also stimulates the production of the hormone erythroferrone (ERFE) which acts to suppress hepcidin production, thus increasing dietary iron absorption and mobilizing stored iron for use in erythropoiesis. ERFE (initially termed myonectin) was also reported have an effect on systemic lipid metabolism by promoting the clearance of nonesterifed fatty acids (NEFA) from circulation. As increased levels of circulating NEFA blunt insulin sensitivity and impair glucose tolerance, ERFE-induced clearance of NEFA after EPO administration would have a beneficial effect on glucose metabolism. The aim of this study was to determine if the known metabolic effect of EPO treatment on glucose homeostasis is mediated by ERFE, produced in response to EPO. Mice lacking Erfe did not differ from wild-type mice in blood lipid parameters, blood glucose, and glucose or insulin tolerance at baseline or after chronic EPO treatment. Additionally, hepcidin suppression and the response of erythrocyte parameters to chronic EPO treatment were unaffected by the absence of Erfe. These findings suggest that the known beneficial effects of EPO on glucose metabolism are not attributable to an accompanying increase in ERFE production, and that Erfe is dispensable for normal glucose homeostasis. Furthermore, our data indicate that ERFE-independent mechanisms can suppress hepcidin in response to chronically elevated EPO levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.